After several months of AbbVie leading pharma’s monthly ad spend, Johnson & Johnson is back as Tremfya topped June’s rankings ...

By Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster ...

After a 7% increase in revenue for the second quarter, which came on the heels of a 10% gain in Q1, Johnson & Johnson has bumped up its annual sales guidance. The company now projects 2026 revenue at ...

Johnson & Johnson's JNJ Immunology franchise remains one of its most important businesses, even as it undergoes a transition amid biosimilar competition targeting its multi-billion-dollar product, ...

Eli Lilly & Company LLY announced superiority of its plaque psoriasis drug Taltz over J&J’s JNJ new drug, Tremfya (guselkumab), in delivering total skin clearance at week 12 in a head-to-head ...